2.87 USD
▼-0.03-3.04%
盘后 2.91 -1.67%
2026-08-03
市值
$141.46M
市盈率
—
EPS
-0.26
股息率
—
52 周区间
0.91 – 4.20
成交量
841.55K
Beta
1.43
目标价
—
52W 低 0.9152W 高 4.20
价格走势
公司简介
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept...